Stock Events

Stock Events

Annovis Bio 

$2.42
55
-$0.06-2.42% Today

Statistics

Day High
2.42
Day Low
2.42
52W High
-
52W Low
-
Volume
2
Avg. Volume
-
Mkt Cap
64.14M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2025
Q4 2025
Next
-0.4
-0.37
-0.34
-0.31
Expected EPS
-0.4
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-49.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANVS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap26.03B
Biogen focuses on neurodegenerative diseases, directly competing with Annovis Bio's Alzheimer's and Parkinson's disease treatments.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly has a strong pipeline in Alzheimer's disease treatments, making it a direct competitor to Annovis Bio.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.78B
Acadia Pharmaceuticals targets central nervous system disorders including Parkinson's disease, competing with Annovis Bio.
Anavex Life Sciences
AVXL
Mkt Cap277.09M
Anavex Life Sciences Corp. works on developing treatments for Alzheimer's disease, directly competing with Annovis Bio.
Axsome Therapeutics
AXSM
Mkt Cap8.62B
Axsome Therapeutics develops novel therapies for central nervous system disorders, including Alzheimer's, making it a competitor.
Prothena
PRTA
Mkt Cap530.79M
Prothena Corporation plc focuses on the development of treatments for neurodegenerative diseases, competing in the same space as Annovis Bio.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals develops RNAi therapeutics for neurodegenerative diseases, positioning it as a competitor to Annovis Bio.
Ionis Pharmaceuticals
IONS
Mkt Cap12.35B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery for neurodegenerative diseases, making it a competitor.

About

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Show more...
CEO
ISIN
US03615A1088

Listings

XNYS
US
ANVS
F
DE
07X.F
BOATS
BOATS
ANVS.BOATS

0 Comments

Share your thoughts

FAQ

What is Annovis Bio stock price today?▼
The current price of ANVS.BOATS is $2.42 USD — it has decreased by -2.42% in the past 24 hours. Watch Annovis Bio stock price performance more closely on the chart.
What is Annovis Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Annovis Bio stocks are traded under the ticker ANVS.BOATS.
What is Annovis Bio market cap?▼
Today Annovis Bio has the market capitalization of 64.14M
When is the next Annovis Bio earnings date?▼
Annovis Bio is going to release the next earnings report on May 19, 2026.
What were Annovis Bio earnings last quarter?▼
ANVS.BOATS earnings for the last quarter are -0.39 USD per share, whereas the estimation was -0.31 USD resulting in a -26.46% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Annovis Bio revenue for the last year?▼
Annovis Bio revenue for the last year amounts to 0 USD.
What is Annovis Bio net income for the last year?▼
ANVS.BOATS net income for the last year is -49.18M USD.
When did Annovis Bio complete a stock split?▼
Annovis Bio has not had any recent stock splits.